Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
Rajat Bannerji(Rutgers, The State University of New Jersey), Max S. Topp(Universitätsklinikum Würzburg), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Srikanth Ambati(Regeneron (United States)), John N. Allan(Cornell University), David M. Weinreich(Regeneron (United States)), Robin Joyce(Beth Israel Deaconess Medical Center), Peter Martin(Northwestern University), Stephen M. Ansell(Mayo Clinic), Ranjana H. Advani(Stanford Medicine), Johannes Duell(Universitätsklinikum Würzburg), George D. Yancopoulos(Regeneron (United States)), Andres Sirulnik(Regeneron (United States)), Min Zhu(Eye & ENT Hospital of Fudan University), Jingjin Li(Inner Mongolia Agricultural University), Dina M. Flink(Progenics Pharmaceuticals (United States)), Aafia Chaudhry(Regeneron (United States)), Susan O’Brien(University of California, Irvine)
Cited by 108
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k